CClinicalTrials.gg
Not yet recruitingNCT07798232MEERCATS 2Updated Sep 3, 2026

Penicillin to Prevent Early Rheumatic Heart Disease in School-Aged Children

A Phase 3 interventional study of Oral Penicillin V in Rheumatic Heart Disease in Children, sponsored by Children's Hospital Medical Center, Cincinnati. Not yet recruiting at 1 site in Uganda. Open to participants aged 5 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 3, Interventional, and Prevention

Phase
Phase 3
Study type
Interventional
Enrollment
9,622
Allocation
Randomized
Ages
5 Years to 8 Years
Sex
All
01

Study summary

This study will look at whether children ages 5-8 who take Penicillin V by mouth twice a day are less likely to develop rheumatic heart disease (RHD) over a 3-year period compared to children who do not take the medicine.

02

Conditions studied

  • Rheumatic Heart Disease in Children

Keywords

  • Rheumatic Heart Disease
  • Pragmatic Randomized Controlled Trial
  • Oral Penicillin V
  • Group A Streptococcus
03

Who can participate

Ages eligible
5 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 5-8 years at enrollment
  • Residence within the participating study catchment area (Gulu District or Gulu City)
  • Normal study echocardiogram confirmed by the expert adjudication panel
  • Parent/guardian able and willing to provide written informed consent
  • Participant able to provide written assent (age 8 years)

Exclusion criteria

Exclusion Criteria:

  • History of prior ARF or RHD with or without cardiac involvement
  • Evidence of RHD on baseline echocardiography
  • Congenital heart disease (excluding small PFO, small ASD) or other cardiac abnormality at baseline echocardiography
  • Self-reported known allergy to penicillin
  • Medical conditions that would preclude safe participation, adherence, or follow-up
  • Anticipated inability to complete 36 months of study follow-up
  • Any known co-morbid condition requiring regular antibiotic prophylaxis
04

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
9,622 participants (estimated)

Study arms

  • Active comparator
    Oral Penicillin V

    Drug: Oral Penicillin V

  • No intervention
    No Prophylaxis

Interventions

  • DrugOral Penicillin V

    Twice-daily oral Pen V 250 mg

05

What researchers measure

Primary outcomes

  1. Cumulative Incidence of Rheumatic Heart Disease

    Proportion of participants with newly diagnosed RHD based on blinded echocardiographic adjudication among children with a normal baseline echocardiogram.

    Time frame: 3 years

Secondary outcomes

  1. Cumulative Incidence of RHD at One Year

    Proportion of participants with newly diagnosed rheumatic heart disease based on blinded echocardiographic adjudication.

    Time frame: 1 year

  2. Number of Participants who Develop Acute Rheumatic Fever

    Percentage of participants who develop acute rheumatic fever (ARF) diagnosed according to the 2015 Revised Jones Criteria among participants in each study arm.

    Time frame: 3 years

  3. Cumulative Incidence of RHD at Two Years

    Proportion of participants with newly diagnosed rheumatic heart disease based on blinded echocardiographic adjudication.

    Time frame: 2 years

  4. Number of Participants who Develop Early RHD

    Proportion of participants who develop Stage A or Stage B rheumatic heart disease as determined by blinded echocardiographic adjudication.

    Time frame: 3 years

  5. Number of Participants who Develop Advanced RHD

    Proportion of participants who develop Stage C or Stage D rheumatic heart disease as determined by blinded echocardiographic adjudication.

    Time frame: 3 years

  6. Number of Participants Experiencing Treatment-Emergent Adverse Events

    Number and proportion of participants experiencing treatment-emergent adverse events, serious adverse events, treatment discontinuations, or other safety-related events attributable to oral Penicillin V.

    Time frame: 3 years

  7. Number of Participants Achieving at least 80% Adherence to Oral Penicillin V Prophylaxis Based on Pill Count

    Proportion of participants assigned to Arm 2 who achieve ≥80% adherence to prescribed oral Penicillin V prophylaxis, as assessed by pill count. At each bimonthly school-based visit, remaining tablets will be counted and adherence calculated as the proportion of prescribed doses taken during the assessment interval.

    Time frame: 3 years

  8. Number of Participants Achieving at Least 80% Adherence to Oral Penicillin V Prophylaxis Based on DoseSmart® Bottle Opening Records

    Proportion of participants assigned to Arm 2 who achieve ≥80% adherence to prescribed oral Penicillin V prophylaxis, as assessed using DoseSmart® electronic bottle opening data downloaded at each bi-monthly visit. Adherence will be calculated as the proportion of expected dosing events recorded over the assessment interval.

    Time frame: 3 years

  9. Number of Participants Achieving at Least 80% Adherence to Oral Penicillin V Prophylaxis Based on Caregiver-Reported Dosing Diary

    Proportion of participants assigned to Arm 2 who achieve ≥80% adherence to prescribed oral Penicillin V prophylaxis, as assessed using a participant/parent paper diary in which caregivers record each administered dose. Adherence will be calculated as the proportion of prescribed doses documented as taken during the assessment interval.

    Time frame: 3 years

06

Study locations

1 site
  • Uganda Heart Institute
    Kampala, Uganda, Uganda
    • Joselyn Rwebembera · Contact · aspaziani@childrensnational.org · 703-347-3271
    • Mary Banks · Contact · 513-803-3123
    • Joselyn Rwebembera · Principal investigator
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07798232
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
The University of Western Australia, Uganda Heart Institute, Ochsner Health System, Murdoch Childrens Research Institute
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Jul 31, 2031 (estimated)
Completion
Mar 1, 2032 (estimated)
Last update
Sep 3, 2026

Study contacts

Alison Spaziani
Contact
aspaziani@childrensnational.org
703-347-3271
Mary Banks
Contact
mary.banks@cchmc.org
Joselyn Rwebembera
principal investigator · Uganda Heart Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion